{
    "id": 5015,
    "name": "fibrolamellar carcinoma",
    "source": "DOID",
    "definition": "A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers. [url:http\\://www.nejm.org/doi/full/10.1056/NEJMra1001683, url:https\\://en.wikipedia.org/wiki/Fibrolamellar_hepatocellular_carcinoma, url:https\\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C4131&ns=NCI_Thesaurus, url:https\\://rarediseases.info.nih.gov/diseases/9396/fibrolamellar-carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5015",
    "evidence": [
        {
            "id": 2072,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring FBXW7 E192A (PMID: 24586741).",
            "molecularProfile": {
                "id": 1539,
                "profileName": "FBXW7 E192A"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5015,
                "name": "fibrolamellar carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2558,
                    "pubMedId": 24586741,
                    "title": "FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24586741"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01396408",
            "title": "A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02234986",
            "title": "A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 727,
                    "therapyName": "ENMD-2076",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04248569",
            "title": "DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9313,
                    "therapyName": "DNAJB1-PRKACA peptide vaccine + Ipilimumab + Nivolumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        }
    ]
}